- Open to men and women above the age of 18 who have been diagnosed with multiple myeloma.
- Participants must not have received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids.
Detailed eligibility will be reviewed when you contact the study team.
This clinical trial is for men and women with newly diagnosed multiple myeloma who are not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT).
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
In this study participants will be randomized to receive either teclistamab or talquetamab or daratumumab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.
Participation is expected to last about 9 years.